Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.

Sevy S, Robinson DG, Napolitano B, Patel RC, Gunduz-Bruce H, Miller R, McCormack J, Lorell BS, Kane J.

Schizophr Res. 2010 Jul;120(1-3):101-7. doi: 10.1016/j.schres.2010.03.037. Epub 2010 May 14.

2.

[Cannabis and schizophrenia: demographic and clinical correlates].

Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.

Encephale. 2003 Jan-Feb;29(1):11-7. French.

PMID:
12640322
3.

Cannabis use disorders in schizophrenia: effects on cognition and symptoms.

DeRosse P, Kaplan A, Burdick KE, Lencz T, Malhotra AK.

Schizophr Res. 2010 Jul;120(1-3):95-100. doi: 10.1016/j.schres.2010.04.007. Epub 2010 May 18.

4.

First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.

Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group.

Schizophr Res. 2004 Feb 1;66(2-3):125-35.

PMID:
15061244
5.

Cannabis use and cognitive functioning in first-episode schizophrenia patients.

Rodríguez-Sánchez JM, Ayesa-Arriola R, Mata I, Moreno-Calle T, Perez-Iglesias R, González-Blanch C, Periañez JA, Vazquez-Barquero JL, Crespo-Facorro B.

Schizophr Res. 2010 Dec;124(1-3):142-51. doi: 10.1016/j.schres.2010.08.017. Epub 2010 Sep 9.

PMID:
20826079
6.

Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.

Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, Martínez-García O, Pardo-García G, Vázquez-Barquero JL.

J Psychiatr Res. 2007 Oct;41(8):659-66. Epub 2006 Jun 23.

PMID:
16797591
7.

Executive attention impairment in adolescents with schizophrenia who have used cannabis.

Epstein KA, Kumra S.

Schizophr Res. 2014 Aug;157(1-3):48-54. doi: 10.1016/j.schres.2014.04.035. Epub 2014 May 27.

8.

Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.

Sevy S, Robinson DG, Sunday S, Napolitano B, Miller R, McCormack J, Kane J.

Psychiatry Res. 2011 Aug 15;188(3):310-4. doi: 10.1016/j.psychres.2011.05.001. Epub 2011 Jun 1.

9.

The relevance of age at first alcohol and nicotine use for initiation of cannabis use and progression to cannabis use disorders.

Behrendt S, Beesdo-Baum K, Höfler M, Perkonigg A, Bühringer G, Lieb R, Wittchen HU.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):48-56. doi: 10.1016/j.drugalcdep.2011.10.013. Epub 2011 Nov 8.

PMID:
22071122
10.

Cannabis use disorder and age at onset of psychosis--a study in first-episode patients.

Schimmelmann BG, Conus P, Cotton SM, Kupferschmid S, Karow A, Schultze-Lutter F, McGorry PD, Lambert M.

Schizophr Res. 2011 Jun;129(1):52-6. doi: 10.1016/j.schres.2011.03.023. Epub 2011 Apr 17.

PMID:
21498049
11.

Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder.

Ringen PA, Nesvåg R, Helle S, Lagerberg TV, Lange EH, Løberg EM, Agartz I, Andreassen OA, Melle I.

Psychol Med. 2016 Nov;46(15):3127-3136. Epub 2016 Aug 18.

PMID:
27534999
12.

[A rare and not very studied disorder: childhood-onset schizophrenia. A case report].

Bailly D, de Chouly de Lenclave MB.

Encephale. 2004 Nov-Dec;30(6):540-7. French.

PMID:
15738856
13.

Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia.

Brousse G, Meary A, Blanc O, Lançon C, Llorca PM, Leboyer M.

Psychiatry Res. 2010 Aug 30;179(1):12-8. doi: 10.1016/j.psychres.2009.03.003. Epub 2010 May 15.

PMID:
20472305
14.

Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects.

Smith MJ, Cobia DJ, Wang L, Alpert KI, Cronenwett WJ, Goldman MB, Mamah D, Barch DM, Breiter HC, Csernansky JG.

Schizophr Bull. 2014 Mar;40(2):287-99. doi: 10.1093/schbul/sbt176. Epub 2013 Dec 15.

15.

The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use.

Coulston CM, Perdices M, Tennant CC.

Schizophr Res. 2007 Nov;96(1-3):169-84. Epub 2007 Sep 10.

PMID:
17826035
16.
17.

Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.

Pelayo-Terán JM, Diaz FJ, Pérez-Iglesias R, Suárez-Pinilla P, Tabarés-Seisdedos R, de León J, Crespo-Facorro B.

Psychol Med. 2014 Jan;44(1):37-50. doi: 10.1017/S0033291713000330. Epub 2013 Mar 6.

PMID:
23461899
18.

The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study.

Machielsen MW, Veltman DJ, van den Brink W, de Haan L.

J Psychopharmacol. 2014 Jul;28(7):633-42. doi: 10.1177/0269881114527357. Epub 2014 Mar 19.

PMID:
24646809
19.

Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder.

Braga RJ, Burdick KE, Derosse P, Malhotra AK.

Psychiatry Res. 2012 Dec 30;200(2-3):242-5. doi: 10.1016/j.psychres.2012.05.025. Epub 2012 Jul 18.

20.

Trajectories and antecedents of treatment response over time in early-episode psychosis.

Levine SZ, Rabinowitz J.

Schizophr Bull. 2010 May;36(3):624-32. doi: 10.1093/schbul/sbn120. Epub 2008 Oct 9.

Supplemental Content

Support Center